The Bionuclear Group S.A. (BNG) was founded in June 1999 as a "life science tank" company. Its strategy was to become one of the most advanced "life science tank" companies in Europe, to provide advanced biotechnology services, to manufacture and distribute novel biotechnology pharmaceuticals, to design and market novel and meaningful -for the patient point of care tests(POCt's) and finally offer a high return to its shareholders for every dollar invested. The company consists of 4 core business units:
Production and distribution of diagnostic and therapeutic radio pharmaceuticals

Research design and development of POCt's

Research, development, clinical trials and registration of novel Biopharmaceuticals

Biotechnology diagnostic reference applications

BNG markets it's POCt product range thru Vitalcheck, a fully owned subsidiary. Vitalcheck strongly believes that these market segments that are poised for a major new phase of growth fueled by the availability of new Biotechnology platforms and the demand for more efficient medical services. Point of care tests, including those for blood glucose, pregnancy, ovulation, coagulation, cholesterol, drugs, infectious disease and various urine components, are in high demand as physicians and patients realize their potential for promoting prevention and delivering improved health care. The POCt market encompasses a large variety of IVD products ranging from moderate sized instrumented diagnostic systems serving larger institutional uses to single-use, disposable tests for individual home use.

Vitalcheck has focused specifically at self test point of care testing areas such as Cholesterol monitoring, HDL Cholesterol, Pregnancy Testing, Drugs of Abuse Screening , Prostate cancer screening, Infectious Disease Testing, HIV, Coagulation Testing and Fertility Testing. It is also intensely involved in research and development of the emerging technologies for point of care diagnostics which are the implications of molecular biology and genomics for new rapid diagnostic tests. Exiting new technology platforms such as Protein Sequencing, DNA sequencing and The Human Genome Project are placed into the context of their impact on rapid diagnosis.